![decoration](/wp-content/themes/yagami-adveris/web/src/img/global/anticorps.png)
![](https://www.minsight-mrd.com/wp-content/uploads/2023/08/ResourcesPublications.webp)
Minimal Residual Disease Monitoring by Targeted Mass Spectrometry Allows Early Relapse Detection in Multiple Myeloma
The dynamic information on disease activity that is provided by the MS-MRD can provide patients with feedback on their disease status after each checkup and can provide clinicians options for evidence-based treatment escalation or de-escalation.